Multi-national pharmaceutical company AstraZeneca International has licensed a database created by Ann Arbor start-up Compendia Bioscience, Inc., created for cancer profiling.

Excerpt:

Officials at Compendia Bioscience Inc. of Ann Arbor said the recent deal with the $69 billion London-based drugmaker takes its product's market penetration into 10 of the top 20 pharma companies in the world.

Read the entire article here.